From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. HIV/AIDS Clinical Care>
  4. News in Context

HIV/AIDS Clinical Care: News in Context

Some content may require paid access to the site. Subscribe or purchase a seven-day site pass for the full text of all our clinical perspectives on medical journal articles, guidelines, and news.


to
Items 1-10 of 39 are shown

New CDC Interim Guidance on HIV and H1N1

HIV-infected individuals are a high-priority group for prevention and treatment of 2009 H1N1 influenza.

  • By Carlos del Rio, MD
  • November 2, 2009
  • Covering:
    • Centers for Disease Control and Prevention (CDC)., 2009 Oct 21

HIV Vaccine Study Shows Promise

A new vaccine regimen, tested among more than 16,000 young adults, was found to offer modest protection against HIV acquisition.

  • By Frances H. Priddy, MD, MPH
  • September 28, 2009
  • Covering:
    • McNeil DG Jr., New York Times 2009 Sep 24
    • U.S. Military HIV Research Program 2009 Sep 24
    • U.S. Military HIV Research Program., 2009 Sep 24
    • U.S. Military HIV Research Program., 2009 Sep 4

Swine-Origin Influenza A (H1N1) and HIV

The CDC offers guidance for HIV-infected patients potentially exposed to swine flu.

  • By Carlos del Rio, MD, and Juan Sierra-Madero, MD
  • May 4, 2009
  • Covering:
    • Centers for Disease Control and Prevention (CDC)., 2009 April 30

Which ART Regimen Is Best After Receipt of Single-Dose Nevirapine?

Preliminary results from the OCTANE trial suggest that lopinavir/r-based regimens are more effective than nevirapine-based ones, particularly when ART is initiated shortly after exposure to single-dose nevirapine.

  • By Catherine Tomeo Ryan
  • November 17, 2008
  • Covering:
    • Bethesda, MD: National Institute of Allergy and Infectious Diseases 2008 Oct 28

Concurrent ART/TB Treatment Finally Proven to Be Beneficial

Giving ART while TB treatment was still ongoing dramatically improved survival among HIV/TB-coinfected patients in a large clinical trial in South Africa.

  • By ACC Editors
  • September 29, 2008
  • Covering:
    • 2008 Sep 19

HIV Vaccine Trial Canceled

NIAID will not conduct the HIV vaccine study known as PAVE 100. Instead, officials are considering a smaller, more focused trial.

  • By Dan H. Barouch, MD, PhD
  • August 4, 2008
  • Covering:
    • 2008 Jul 17

FTC + Atazanavir + ddI Deemed Inferior to AZT/3TC + Efavirenz

Patients receiving FTC + atazanavir + ddI in an ongoing ACTG trial are being switched to other regimens but will continue to be followed.

  • By Paul E. Sax, MD
  • June 9, 2008
  • Covering:
    • National Institute of Allergy and Infectious Diseases., 2008 May 27

Abacavir/3TC vs. Tenofovir/FTC: Interim Results from ACTG 5202

An interim analysis from ACTG 5202 suggests that abacavir/3TC is not as effective as tenofovir/FTC in reducing viral load among treatment-naive patients with high viral loads (100,000 or more copies/mL) at baseline.

HIV-1 Vaccine Might Increase Infection Risk in Certain Subgroups

The HIV-1 vaccine used in the STEP trial has already been shown to be ineffective, but might it actually cause harm?

HIV-1 Vaccine Candidate Ineffective

The vaccine used in the international STEP trial failed to prevent HIV-1 infection and also did not reduce viral load in those who became infected.

  • By Dan H. Barouch, MD, PhD
  • October 1, 2007
  • Covering:
    • 2007 Sep 21
Items 1-10 of 39 are shown

to

Search

Advanced

Sign-In

Forgot your password?

New to Journal Watch?





Copyright © 2009. Massachusetts Medical Society. All rights reserved.